This study is accepting new patients by invitation only
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
Summary
- Eligibility
- for males ages 2 years and up (full criteria)
- Location
- at UC Davis
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients by invitation only
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Sarepta Therapeutics, Inc.
- ID
- NCT04626674
- Phase
- Phase 1 Duchenne Muscular Dystrophy Research Study
- Study Type
- Interventional
- Participants
- Expecting 58 study participants
- Last Updated